3-[3-(imidazolo)propoxy]benzenamine | 210917-99-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-[3-(imidazolo)propoxy]benzenamine
• 英文别名: 3-[3-imidazo-1-ylpropyloxyl]-aniline；3-(3-Imidazol-1-ylpropoxy)aniline
• CAS: 210917-99-0
• 化学式: C₁₂H₁₅N₃O
• mdl: MFCD11652480
• 分子量: 217.271
• InChiKey: FSIOXADZPRTTCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  53.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-[3-(imidazolo)propoxy]benzenamine 、 3-hydroxy-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione 在 溶剂黄146 作用下， 生成 3-[3-(3-imidazol-1-ylpropoxy)anilino]-4-(1H-indol-3-yl)pyrrole-2,5-dione
  参考文献：
  名称：

  Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors

  摘要：

  We designed a series of anilino-indoylmaleimides based on structural elements from literature JAK3 inhibitors 3 and 4, and our lead 5. These new compounds were tested as inhibitors of JAKs 1, 2 and 3 and TYK2 for therapeutic intervention in rheumatoid arthritis (RA). Our requirements, based on current scientific rationale for optimum efficacy against RA with reduced side effects, was for potent, mixed JAK1 and 3 inhibition, and selectivity over JAK2. Our efforts yielded a potent JAK3 inhibitor 11d and its eutomer 11e. These compounds were highly selective for inhibition of JAK3 over JAK2 and TYK. The compounds displayed only modest JAK1 inhibition. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.001
• 作为产物：
  描述：

  1-(3-溴丙氧基)-3-硝基苯 在 palladium 10% on activated carbon 、 氢气 、 sodium hydride 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-[3-(imidazolo)propoxy]benzenamine
  参考文献：
  名称：

  Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors

  摘要：

  We designed a series of anilino-indoylmaleimides based on structural elements from literature JAK3 inhibitors 3 and 4, and our lead 5. These new compounds were tested as inhibitors of JAKs 1, 2 and 3 and TYK2 for therapeutic intervention in rheumatoid arthritis (RA). Our requirements, based on current scientific rationale for optimum efficacy against RA with reduced side effects, was for potent, mixed JAK1 and 3 inhibition, and selectivity over JAK2. Our efforts yielded a potent JAK3 inhibitor 11d and its eutomer 11e. These compounds were highly selective for inhibition of JAK3 over JAK2 and TYK. The compounds displayed only modest JAK1 inhibition. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.001

文献信息

• Cyclic protein tyrosine kinase inhibitors
  申请人：——

  公开号：US20040054186A1

  公开（公告）日：2004-03-18

  Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.

  新型环状化合物及其盐类，含有此类化合物的药物组合物，以及使用此类化合物治疗蛋白质酪氨酸激酶相关疾病，如免疫和肿瘤疾病的方法。
• [EN] INHIBITORS OF TYROSINE KINASES<br/>[FR] INHIBITEURS DE TYROSINE KINASES
  申请人：NOVARTIS AG

  公开号：WO2004005281A1

  公开（公告）日：2004-01-15

  The invention relates to compounds of formula (I) Wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such disease.

  该发明涉及式(I)的化合物，其中取代基R1、R2和R4的含义如所述并在发明说明中解释，以及制备这些化合物的方法，含有相同化合物的药物组合物，其可选择与一个或多个其他药用活性化合物结合使用，用于治疗对蛋白激酶活性抑制产生反应的疾病，尤其是肿瘤性疾病，特别是白血病，以及用于治疗此类疾病的方法。
• Design, synthesis and biological evaluation of selected 3-[3-(amino) propoxy] benzenamines as acetylcholinesterase inhibitors
  作者：Ruchi Malik、Richa Gupta、Shubham Srivastava、Bhanwar Singh Choudhary、Manish Sharma

  DOI：10.1080/07391102.2016.1220330

  日期：2017.8.18

  relaxant, analgesic and anticonvulsant activities). Compound 3-[3-(imidazolo)propoxy]benzenamine has shown significant dose-dependent (1 and 3 mg/kg) memory enhancing activity, while 3-[3-(pyrrolidino)propoxy]benzenamine also showed activity equivalent to reference drug piracetam at 1 mg/kg. Both compounds 3-[3-(pyrrolidino)propoxy]benzenamine and 3-[3-(imidazolo)propoxy]benzenamine were also found to show

  本文描述了一系列的3- [3-（氨基）丙氧基]苯甲胺类作为乙酰胆碱酯酶抑制剂的设计，合成和生物学评估，以小鼠为模型，吡拉西坦为参比药物。这些化合物的结构通过光谱分析确认，并使用升高的迷宫测试和乙酰胆碱酯酶抑制试验测试化合物的记忆增强活性。合成化合物的抑制范围为8.99至28.31μM。与吡乙酰胺相比，合成的化合物在1 mg / kg的条件下具有比吡乙酰胺更高或相当的保留率，并且没有其他与CNS相关的活性（运动和肌肉松弛，镇痛和抗惊厥活性）。化合物3- [3-（咪唑基）丙氧基]苯胺已显示出显着的剂量依赖性（1和3 mg / kg）记忆增强活性，而3- [3-（吡咯烷基）丙氧基]苯甲胺也显示出与参考药物吡拉西坦相当的活性，为1 mg / kg。还发现化合物3- [3-（吡咯烷基）丙氧基]苯胺和3- [3-（咪唑基）丙氧基]苯胺都显示出IC对AChE的抑制作用50值为8.99和17.87μM。为
• [EN] HETEROARYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLE ET UTILISATIONS ASSOCIÉES
  申请人：AVILA THERAPEUTICS INC

  公开号：WO2011090760A1

  公开（公告）日：2011-07-28

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了化合物，其药物学上可接受的组成物以及使用它们的方法。
• Inhibitors of tyrosine kinases
  申请人：NOVARTIS AG

  公开号：EP2100891A1

  公开（公告）日：2009-09-16

  The invention relates to compounds of formula wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such a disease.

  本发明涉及公式的化合物，其中置换基R1、R2和R4的含义如本发明说明书中所述和解释的那样，以及制备这些化合物的过程，包含它们的制药组合物，其可选择与一个或多个其他药物活性化合物联合使用，用于治疗对蛋白激酶活性抑制有反应的疾病，尤其是肿瘤性疾病，特别是白血病，并且提供了一种治疗这种疾病的方法。